Conditions: ADHD
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 269
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).

Detailed description:
Not Required

Arms:
arm 1: Lisdexamfetamine Dimesylate (LDX)

Interventions: intervention 1: Lisdexamfetamine Dimesylate (LDX)
Intervention descriptions: intervention 1: optimal dose of 30, 50 or 70 mg once daily

Protocol document: